NEUROFIBROMATOSIS TYPE 2
Clinical trials for NEUROFIBROMATOSIS TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMATOSIS TYPE 2 trials appear
Sign up with your email to follow new studies for NEUROFIBROMATOSIS TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising NF2 meningioma drug trial halted early
Disease control TerminatedThis study tested an experimental drug called REC-2282 in people aged 12 and older with progressive meningiomas linked to NF2 gene mutations. The goal was to see if the drug could slow tumor growth or improve survival. The trial was terminated early, so final results are not avai…
Matched conditions: NEUROFIBROMATOSIS TYPE 2
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 04:23 UTC
-
Experimental drug AR-42 tested in tiny brain tumor study
Knowledge-focused TerminatedThis early study tested the drug AR-42 in 7 adults with vestibular schwannoma or meningioma who were already scheduled for tumor removal surgery. The goal was to see if the drug could lower a protein linked to tumor growth. The study was stopped early, so results are limited.
Matched conditions: NEUROFIBROMATOSIS TYPE 2
Phase: EARLY_PHASE1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Knowledge-focused
Last updated May 17, 2026 04:17 UTC